Market Closed -
Sao Paulo
04:07:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
5.91
BRL
|
-0.17%
|
|
-3.11%
|
-3.11%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
481.9
|
793.3
|
747.9
|
723.4
|
450
|
747.9
|
Enterprise Value (EV)
1 |
888.7
|
1,465
|
1,277
|
1,482
|
1,291
|
1,698
|
P/E ratio
|
-47.3
x
|
66.2
x
|
14.3
x
|
9.25
x
|
5.56
x
|
10.6
x
|
Yield
|
-
|
-
|
-
|
4.59%
|
4.72%
|
1.9%
|
Capitalization / Revenue
|
0.11
x
|
0.17
x
|
0.14
x
|
0.11
x
|
0.06
x
|
0.09
x
|
EV / Revenue
|
0.21
x
|
0.31
x
|
0.23
x
|
0.23
x
|
0.17
x
|
0.2
x
|
EV / EBITDA
|
10.5
x
|
11.6
x
|
8.52
x
|
9.11
x
|
4.54
x
|
5.74
x
|
EV / FCF
|
-111
x
|
-55
x
|
-50.4
x
|
-136
x
|
-22.6
x
|
-101
x
|
FCF Yield
|
-0.9%
|
-1.82%
|
-1.98%
|
-0.73%
|
-4.42%
|
-0.99%
|
Price to Book
|
0.47
x
|
0.79
x
|
0.71
x
|
0.67
x
|
0.38
x
|
0.6
x
|
Nbr of stocks (in thousands)
|
122,611
|
122,611
|
122,611
|
122,611
|
122,611
|
122,611
|
Reference price
2 |
3.930
|
6.470
|
6.100
|
5.900
|
3.670
|
6.100
|
Announcement Date
|
3/21/19
|
3/11/20
|
3/16/21
|
3/16/22
|
3/15/23
|
3/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
4,271
|
4,801
|
5,481
|
6,413
|
7,816
|
8,662
|
EBITDA
1 |
84.9
|
126.5
|
149.9
|
162.7
|
284.2
|
295.6
|
EBIT
1 |
64.43
|
105.5
|
128.3
|
136.3
|
253.8
|
261.1
|
Operating Margin
|
1.51%
|
2.2%
|
2.34%
|
2.12%
|
3.25%
|
3.01%
|
Earnings before Tax (EBT)
1 |
-30.13
|
21.56
|
33.15
|
48.75
|
78.97
|
81.59
|
Net income
1 |
-9.734
|
11.98
|
52.33
|
78.19
|
80.87
|
70.4
|
Net margin
|
-0.23%
|
0.25%
|
0.95%
|
1.22%
|
1.03%
|
0.81%
|
EPS
2 |
-0.0831
|
0.0977
|
0.4268
|
0.6377
|
0.6596
|
0.5740
|
Free Cash Flow
1 |
-8.034
|
-26.62
|
-25.32
|
-10.87
|
-57.05
|
-16.86
|
FCF margin
|
-0.19%
|
-0.55%
|
-0.46%
|
-0.17%
|
-0.73%
|
-0.19%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.2706
|
0.1733
|
0.1157
|
Announcement Date
|
3/21/19
|
3/11/20
|
3/16/21
|
3/16/22
|
3/15/23
|
3/7/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
407
|
672
|
529
|
758
|
841
|
950
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
4.792
x
|
5.307
x
|
3.528
x
|
4.661
x
|
2.959
x
|
3.213
x
|
Free Cash Flow
1 |
-8.03
|
-26.6
|
-25.3
|
-10.9
|
-57
|
-16.9
|
ROE (net income / shareholders' equity)
|
-1.1%
|
1.18%
|
5.07%
|
5.44%
|
5.69%
|
5.11%
|
ROA (Net income/ Total Assets)
|
1.46%
|
2.17%
|
2.31%
|
2.19%
|
3.78%
|
3.51%
|
Assets
1 |
-665.9
|
551.9
|
2,267
|
3,578
|
2,141
|
2,006
|
Book Value Per Share
2 |
8.330
|
8.190
|
8.530
|
8.860
|
9.710
|
10.20
|
Cash Flow per Share
2 |
1.870
|
1.840
|
3.030
|
1.540
|
1.490
|
1.580
|
Capex
1 |
12.1
|
21.4
|
36
|
68.5
|
60
|
67.5
|
Capex / Sales
|
0.28%
|
0.45%
|
0.66%
|
1.07%
|
0.77%
|
0.78%
|
Announcement Date
|
3/21/19
|
3/11/20
|
3/16/21
|
3/16/22
|
3/15/23
|
3/7/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.11% | 136M | | -32.86% | 14.96B | | -23.15% | 11.07B | | +9.74% | 6.13B | | -22.64% | 6.08B | | -10.91% | 5.98B | | +0.88% | 4.76B | | +53.60% | 4.36B | | -10.49% | 3.73B | | -12.53% | 3.43B |
Other Drug Retailers
|